

ABSTRACT

The present disclosure relates to the field of biomedicine, and relates to a use of an ADC targeting HER2 in the treatment of breast cancer. The present disclosure also relates to a method for treating breast cancer in a subject, said method comprising: administering an anti-HER2 ADC to a subject. The present disclosure further relates to a use of the anti-HER2 ADC in the preparation of a drug for neoadjuvant therapy of breast cancer. The method is beneficial to breast cancer subjects and has good safety.

No Figure.